Lagarde Michel 4

What Happened

• Michel Lagarde, a director of Vertex Pharmaceuticals (VRTX), was reported to have acquired 2,866 shares as an award on 2026-05-01. The filing lists the acquisition price as $0.00 (derivative securities), and a footnote states the shares are fully vested, meaning he received immediate ownership of the shares. This was an equity award (compensation grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-05 (timely filing, within the two-business-day requirement).
• Shares acquired: 2,866; price reported: $0.00; total reported cash cost: $0 (derivative acquisition).
• Footnote: F1 — Fully vested.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Type of transaction code: A (award/grant/acquisition of derivative securities).

Context

• Director equity awards are commonly part of board compensation and are routine; they do not necessarily signal a buy/sell decision by the insider.
• The filing lists a derivative acquisition (likely an RSU or similar award settled into common stock) that vested immediately per the footnote, resulting in direct ownership of the shares.